A micro-cap “apparel” stock at the brink of a clinically-validated, retailer-scaled materials-science step-change.
Overview
iFabric has evolved from a niche intimate-apparel distributor into a high-growth “intelligent textiles” company combining proprietary chemistry with branded finished goods. The business is now driven primarily by Intelligent Fabric Technologies (IFTNA), which sells treatments like PROTX2 (zinc-based antimicrobial designed to be permanent) and ecoPEL (fluorine-free water repellency aligned with PFAS bans), and also sells technology-enhanced apparel—especially clinically validated medical scrubs through mass retail channels. A pivotal credibility driver is peer-reviewed clinical evidence: a 2025 Journal of Hospital Infection study showed statistically significant reductions in bacterial contamination from PROTX2-treated scrubs in real healthcare settings. The company is entering an inflection point with raised Q1 2026 revenue guidance of $25–$27M, implying a structural scale change versus historical run-rates and setting up a potential valuation re-rating if margins normalize and execution holds.